Apr 25 |
Azvudine for COVID-19: real-time meta analysis of 18 studies | |
| Statistically significant lower risk is seen for mortality, ventilation, ICU admission, progression, and viral clearance. 14 studies from 12 independent teams in 2 countries show statistically significant improvements. Meta analysis using.. | ||
Apr 1 |
et al., Research Square, doi:10.21203/rs.3.rs-4157424/v1 | Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study |
| 35% lower mortality (p=0.05). Retrospective 2,862 hospitalized COVID-19 patients in China showing lower mortality with azvudine treatment. | ||
Mar 4 |
et al., Journal of Cancer, doi:10.7150/jca.91530 | A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer |
| 11% shorter hospitalization (p=0.26) and 50% improved viral clearance (p=0.03). PSM retrospective 84 hospitalized COVID-19 patients with pre-existing cancer in China, showing faster viral clearance with azvudine. There was no significant difference in length of hospital stay or ICU admission. | ||
Feb 23 |
et al., Virology Journal, doi:10.1186/s12985-024-02316-y | Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis |
| Systematic review and meta-analysis of 17 studies showing significantly lower mortality with azvudine compared to no antiviral treatment in COVID-19 patients. The mortality benefit was seen in both mild/moderate and severe disease, as wel.. | ||
Feb 12 |
et al., Journal of Clinical Pharmacology and Therapeutics, 5:1 | Effects of Azvudine on the Low-Risk Patients Infected with COVID-19 Omicron Variants: A Retrospective Case-Control Study |
| 1% slower recovery (p=0.9). Retrospective 481 low-risk COVID-19 patients in China showing no significant difference in recovery or symptomatic severity with azvudine, but slightly lower total viral load. | ||
Feb 9 |
et al., Scientific Reports, doi:10.1038/s41598-024-53862-y | Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study |
| Retrospective 157 hospitalized mild-to-moderate COVID-19 patients showing no significant differences between azvudine, molnupiravir, and paxlovid for time to viral clearance and length of hospitalization. | ||
Feb 9 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102468 | Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study |
| 20% lower mortality (p=0.44) and 3% lower progression (p=0.91). Retrospective 249 elderly patients with severe COVID-19, 128 treated with azvudine, 66 treated with paxlovid, and 55 receiving neither treatment, showing no significant differences for Ct value changes, progression, or survival for either.. | ||
Jan 18 |
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2024.107096 | Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis |
| Systematic review and network meta-analysis of 160 studies involving over 900,000 COVID-19 patients assessing the efficacy and safety of small-molecule antivirals. For azvudine, significant benefits were found for mortality, mechanical ve.. | ||
Jan 5 |
et al., Research Square, doi:10.21203/rs.3.rs-3707560/v1 | Risk of severe case in COVID-19 patients and Azvudine: A Retrospective cohort study after exit from ‘zero-COVID’ policy |
| 29% lower mortality (p=0.03). Retrospective 4,201 hospitalized COVID-19 patients in China, showing lower mortality with azvudine. | ||
Nov 7 2023 |
et al., Heliyon, doi:10.1016/j.heliyon.2023.e21941 | Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study |
| Retrospective 60 hospitalized COVID-19 patients in China, 32 treated with azvudine for 7-14 days. The azvudine group had impoved eosinophil counts, CRP, IL-6, fibrinogen, NT-proBNP, and improved lung CT findings, suggesting reduced inflam.. | ||
Oct 21 2023 |
et al., Heliyon, doi:10.1016/j.heliyon.2023.e21387 | Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients |
| 24% lower progression (p=0.44). Retrospective 572 fully vaccinated hospitalized patients in China, showing lower risk with azvudine treatment, without statistical significance. The composite outcome included intubation, non-invasive respiratory support, ICU admission, a.. | ||
Oct 19 2023 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1215916 | Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients |
| 82% improved recovery (p=0.01) and 13% faster viral clearance (p=0.03). RCT 179 hospitalized patients in Brazil, showing improved recovery with azvudine treatment. | ||
Oct 13 2023 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1274294 | Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching |
| no change in mortality (p=1), 28% lower ventilation (p=0.04), 55% lower ICU admission (p=0.05), and 22% lower progression (p=0.07). PSM retrospective 725 hospitalized COVID-19 patients in China compared the effectiveness and safety of the oral antivirals azvudine and paxlovid. There was no significant difference in the risk of disease progression between groups, but a.. | ||
Oct 12 2023 |
et al., Frontiers in Microbiology, doi:10.3389/fmicb.2023.1280026 | Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China |
| 22% lower mortality (p=0.15). Retrospective 322 hospitalized patients ≥65 in China, showing lower mortality with azvudine treatment, without statistical significance. | ||
Sep 30 2023 |
et al., Infection and Drug Resistance, doi:10.2147/IDR.S423725 | Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study |
| Retrospective propensity-matched analysis of 227 COVID-19 patients in Tibet, China comparing azvudine to paxlovid. Overall, azvudine had comparable viral clearance time and clinical outcomes to paxlovid. However, for mild COVID-19 cases, .. | ||
Aug 31 2023 |
et al., Journal of Infection, doi:10.1016/j.jinf.2023.05.012 | Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities |
| 64% lower mortality (p=0.11), 67% lower ventilation (p=0.28), and 48% lower progression (p=0.03). Retrospective 2,118 hospitalized COVID-19 patients in China, showing improved results with azvudine vs. paxlovid. | ||
Aug 24 2023 |
, K., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1228548 | Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials |
| Review of four phase III clinical trials evaluating the efficacy and safety of azvudine, a nucleoside analog, for the treatment of COVID-19. The trials were conducted in China, Russia, and Brazil on patients with mild to moderate disease... | ||
Jul 23 2023 |
et al., Microorganisms, doi:10.3390/microorganisms11071859 | Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China |
| 56% lower mortality (p=0.007). Retrospective 1,082 severely and critically ill COVID-19 patients in China showing lower 60 day mortality with azvudine. Mortality was also lower with paxlovid, but without statistical significance, and health related quality of life was.. | ||
Jul 20 2023 |
et al., Journal of Medical Virology, doi:10.1002/jmv.28947 | Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study |
| 91% lower mortality (p=0.09), 75% lower hospitalization (p=0.05), and 16% improved recovery (p=0.19). PSM retrospective 804 high-risk, nonhospitalized adults with mild to moderate COVID-19 in China. The study compared outcomes between 317 patients who received azvudine with 487 patients who received standard supportive treatment only. The.. | ||
Jul 14 2023 |
et al., Research Square, doi:10.21203/rs.3.rs-3145554/v1 | Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China |
| 37% lower mortality (p=0.05) and 3% greater improvement (p=0.73). PSM retrospective 6,218 hospitalized COVID-19 patients in China showing lower 28-day all-cause mortality with azvudine treatment compared to controls (HR 0.63, 95% CI 0.40-1.00). Subgroup analysis found significantly faster clinical impro.. | ||
Jul 13 2023 |
et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2023.07.007 | Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study |
| 62% lower mortality (p=0.0002). PSM retrospective 1072 hospitalized patients with COVID-19 pneumonia in China, showing lower mortality with azvudine treatment. | ||
May 5 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101981 | Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study |
| 54% lower mortality (p=0.16), 38% lower need for oxygen therapy (p=0.15), and 48% lower progression (p=0.02). PSM retrospective 490 hospitalized COVID-19 patients with pre-existing conditions in China showing that azvudine was associated with a significantly lower risk of the composite outcome of disease progression, driven largely by lower rates.. | ||
Apr 30 2023 |
et al., Cardiology Plus, doi:10.1097/CP9.0000000000000049 | All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis |
| 6% lower mortality (p=0.88). PSM retrospective 332 hospitalized moderate to critically ill COVID-19 patients with myocardial injury in China, showing improved 14 day mortality but no difference in overall in-hospital mortality with azvudine treatment. | ||
Jan 23 2023 |
et al., medRxiv, doi:10.1101/2023.01.23.23284899 | Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study |
| 74% lower mortality (p=0.04), 91% lower ventilation (p=0.06), 75% lower ICU admission (p=0.37), and 57% lower progression (p=0.05). PSM retrospective 900 hospitalized COVID-19 patients in China showing lower risk of disease progression and death with azvudine treatment. | ||
Jan 6 2023 |
et al., medRxiv, doi:10.1101/2023.01.05.23284180 | Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study |
| 12% slower recovery (p=0.95) and 32% improved viral clearance (p=0.04). Retrospective 207 COVID-19 patients in China, showing azvudine associated with faster viral clearance, with azvudine-treated patients obtaining a negative PCR test result 1.7 days faster on average compared to supportive care alone after .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.